Ipsen Reports P-III (NAPOLI 3) Trial Results of Onivyde for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Shots:
- The P-III (NAPOLI 3) trial evaluates Onivyde (irinotecan liposome inj.) + 5 fluorouracil/leucovorin and oxaliplatin vs nab-paclitaxel + gemcitabine in 770 patients with mPDAC
- The trial met its 1EPs i.e., improvement in OS. The secondary efficacy outcome of PFS also showed significant improvement while the safety profile was consistent with that observed in the prior P-I/II study for mPDAC
- The company plans to file the sNDA of Onivyde + oxaliplatin & 5- fluorouracil/leucovorin with the US FDA for the same indication. Onivyde has been approved in major markets incl. the US, EU & Asia in combination with 5-FU and LV for metastatic pancreatic adenocarcinoma
Ref: Ipsen | Image: Ipsen
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
